Physician profile
John O Frame
NPI 1699799015
$8,033.76
in general payments reported to CMS, 2019-2025
37 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $1,141 · 2021: $1,220 · 2022: $1,033 · 2023: $1,185 · 2024: $1,119 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,614.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,309.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,055.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,029.20 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $781.04 | 2021-2025 | |
| Amgen INC. | $548.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.12 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $316.97 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $306.60 | 2019-2023 | |
| Dexcom, INC. | $302.91 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $219.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $202.60 | 2019-2022 | |
| Exact Sciences Corporation | $165.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $158.54 | 2019-2021 | |
| Pfizer INC. | $153.19 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $132.57 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Frame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.